Oxford Biomedica plc (OXB.L)

322,00 +2,00 (+0,63%) Alla chiusura: 04:35PM BST

Oxford Biomedica plc

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000
https://www.oxb.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 714

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Stuart Paynter	CFO & Director	832k	N/D	1972
Dr. Frank Mathias	CEO & Director	N/D	N/D	1962
Mr. Thierry Cournez	COO & Oxford Site Head	N/D	N/D	N/D
Dr. James Miskin Ph.D.	Chief Quality & Technical Officer	N/D	N/D	N/D
Mr. Matthew Treagus	Chief Information Officer	N/D	N/D	N/D
Sophia Bolhassan	Head of Investor Relations	N/D	N/D	N/D
Ms. Natalie Louise Walter	General Counsel & Company Secretary	N/D	N/D	1973
Ms. Lisa James	Chief People Officer	N/D	N/D	N/D
Dr. Kyriacos Mitrophanous Ph.D.	Chief Innovation Officer	N/D	N/D	N/D
Ms. Kati Hudson	Head of Intellectual Property and Contracts	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Oxford Biomedica plc al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 6; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.